

Innovation all for the patients



Roche A member of the Roche group

Galderma Announces Updates on Nemolizumab Development

TOKYO, October 12, 2023 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Galderma](#) issued a press release on October 11 regarding data of phase III clinical studies, in atopic dermatitis (ARCADIA 1/2) and prurigo nodularis (OLYMPIA 1) at EADV (European Academy of Dermatology & Venereology) congress being held in Berlin, Germany, for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma.

Please refer to the link below for details of the Galderma's press release:

Galderma @ EADV 2023: phase III trials demonstrate nemolizumab's efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis

[https://www.galderma.com/news/galderma-eadv-2023-phase-iii-trials-demonstrate-nemolizumabs-
efficacy-and-rapid-onset-action](https://www.galderma.com/news/galderma-eadv-2023-phase-iii-trials-demonstrate-nemolizumabs-efficacy-and-rapid-onset-action)

###